Food-Grade Exosome Functional & Stability Evaluation

Q: Do you offer evaluation of food-grade mEV function?

Our core evaluation platform focuses on in vitro and ex vivo models, which provide the standardized, reproducible data most commonly required for GRAS and novel food dossiers. For clients requiring in vivo confirmation, we offer tiered pathways into pharmacokinetic biodistribution studies, acute and subchronic oral toxicity assessment, and disease-model efficacy testing in rodent models. These services are scoped and quoted on a project-specific basis and can integrate with our Exosome Functional Validation & Mechanism of Action Studies platform.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

A mEV preparation that passes food-safety testing is necessary but not sufficient—the product must also survive gastrointestinal transit and exert measurable health benefits at the target site. At Creative BioMart Microbe, our Food-Grade Exosome Functional & Stability Evaluation services provide the evidence bridge between safety-tested production batches and substantiated health-related product claims. We simulate the full oral-to-intestinal journey using physiologically relevant digestion models, then assess post-digestion bioactivity across gut barrier integrity, immunomodulation, and anti-inflammatory endpoints using standardized cell-based and ex vivo assay platforms.

This integrated evaluation package moves beyond simple particle counting after digestion. We quantify cargo integrity retention, measure dose-dependent functional responses in intestinal epithelial and immune cell models, and benchmark potency across strains and production batches—providing the quantitative efficacy data required for GRAS health claim substantiation, product differentiation, and regulatory dossier support. For clients requiring in vivo confirmation, we offer tiered evaluation pathways extending into pharmacokinetic biodistribution studies and disease-model efficacy testing in relevant animal models. Contact us to design a functional evaluation program for your food-grade mEV product.

Scientific schematic of the food-grade exosome functional and stability evaluation platform showing simulated GI digestion, post-digestion cargo integrity analysis, gut barrier assays, immunomodulation profiling, and comparative batch benchmarking arranged along a workflow with data visualization panels.
Figure 1. Schematic overview of the food-grade exosome functional and stability evaluation platform, integrating simulated gastrointestinal digestion, post-digestion cargo integrity analysis, intestinal barrier function assays, immunomodulatory profiling, and comparative batch benchmarking into a comprehensive efficacy assessment framework.

Services

Service Workflow

Our evaluation workflow applies a sequential, physiologically grounded framework: digestive stability is assessed first to define the surviving fraction, then post-digestion cargo integrity confirms that bioactive molecules remain intact, and finally functional assays measure whether the surviving, cargo-intact mEVs exert their intended biological effects. Each module generates quantitative, dose-response data suitable for product dossiers and regulatory submissions.

Horizontal process flowchart showing six steps of food-grade exosome functional evaluation: Sample Receipt, Simulated GI Digestion, Post-Digestion Particle Characterization, Cargo Integrity Analysis, Functional Bioactivity Assays, and Comparative Analysis & Reporting.

Inquiry

Service Details

3D illustration of a sequential digestion apparatus showing stomach and intestinal phase chambers with pH indicators, enzyme vials, and a particle tracking readout displaying pre- and post-digestion size distribution curves.

Simulated Gastrointestinal Digestion Stability Assessment

We assess mEV survival through sequential exposure to simulated gastric and intestinal fluids using standardized INFOGEST-aligned protocols. At each digestion phase and the final post-digestion endpoint, particle concentration, size distribution, and surface charge are measured by nanoparticle tracking analysis and dynamic light scattering. Results are reported as phase-specific survival percentages with particle integrity metrics, and protective formulation strategies are recommended based on observed degradation patterns.

3D illustration of a split analytical view showing a Western blot band pattern on the left and a qPCR amplification curve with a small RNA sequencing readout on the right, all focused on cargo molecule integrity.

Post-Digestion Cargo Integrity Analysis

Structural survival of the vesicle does not guarantee that encapsulated bioactive cargo remains functional. After simulated digestion, we extract total RNA and protein from the surviving mEV fraction and quantify key cargo molecules by qPCR, Western blot, and targeted metabolomics. Cargo retention is reported as the percentage of each analyte remaining relative to the undigested reference, providing molecular-level evidence of functional payload protection through GI transit.

3D illustration of a Caco-2 intestinal epithelial monolayer with tight junction protein visualization, a TEER measurement electrode, and repair indicators showing barrier restoration after EV treatment.

Gut Barrier Integrity & Repair Assays

We evaluate the ability of post-digestion mEVs to reinforce or repair intestinal epithelial barrier function using established intestinal cell monolayer models. Barrier integrity is monitored by transepithelial electrical resistance, and tight junction protein expression is quantified by immunofluorescence and gene expression analysis. Results are benchmarked against positive controls, providing quantitative barrier repair efficacy data for gut health product positioning.

3D illustration of immune cells with cytokine release indicators, showing a shift from pro-inflammatory to anti-inflammatory profiles with color-coded cytokine readout panels.

Immunomodulation & Anti-Inflammatory Profiling

The gut hosts the body's largest immune interface, and food-grade mEVs must demonstrate favorable immunomodulatory activity. We profile post-digestion mEVs across multiple immune endpoints using macrophage and dendritic cell models, including cytokine induction profiling by multiplex assay, immune polarization screening, and NF-κB pathway activation reporters. Dose-response curves identify effective concentration ranges, and results are benchmarked against established immunomodulatory positive controls.

3D illustration of a multi-panel data dashboard with bar charts comparing EV potency across strains, a radar plot showing multi-parameter batch consistency, and ranking indicators.

Comparative Strain & Batch Functional Benchmarking

Not all production strains generate mEVs of equivalent potency, and batch-to-batch variation can undermine product consistency claims. We run head-to-head functional comparisons across strains, fermentation conditions, or production batches using a standardized multi-endpoint assay panel. Results are delivered as potency rankings, batch consistency metrics, and statistical significance assessments that identify the highest-performing strain and validate batch reproducibility for regulatory and marketing documentation.

Service Specifications & QC Standards

Instrumentation & Analytical Capability

Simulated Digestion: INFOGEST-aligned static digestion model with sequential gastric and intestinal phases under controlled temperature and pH.
Nanoparticle Analysis: NTA and DLS for pre- and post-digestion particle concentration, size distribution, and polydispersity.
Cargo Analysis: qPCR for sRNA quantification, Western blot for protein cargo, targeted LC-MS/MS for metabolite retention.
Barrier Function: TEER measurement systems, immunofluorescence microscopy for tight junction protein localization, RT-qPCR for gene expression quantification.
Immunomodulation: Multiplex bead array for cytokine profiling, flow cytometry for immune cell surface marker analysis, NF-κB luciferase reporter assays.
Cell Culture Platforms: Caco-2 intestinal epithelial monolayers, THP-1-derived macrophage models, primary dendritic cell cultures, DC–T cell co-culture systems.
Data Analysis: Dose-response curve fitting, potency ranking algorithms, batch consistency statistical analysis (CV, ANOVA).

Representative Performance Indicators

Gastric phase particle retention varies significantly by strain and formulation, with higher retention generally observed in optimized matrices.
Full GI transit survival depends on vesicle composition and protective formulation strategy.
Cargo retention post-digestion is analyte-specific, with sRNA, protein, and metabolite classes showing differential stability profiles.
Barrier repair efficacy in intestinal epithelial models is dose-dependent and benchmarked against positive controls.
Tight junction protein expression responds to post-digestion mEV treatment in a strain-specific manner.
Anti-inflammatory cytokine induction and pro-inflammatory cytokine suppression are endpoint-specific and concentration-dependent.
Inter-strain potency differences are routinely observed and quantified through head-to-head screening.
Batch-to-batch functional consistency is monitored across replicate production campaigns.

Turnaround Time

Service Module	Timeline
GI stability assessment (single strain, one formulation)	2–3 weeks
Post-digestion cargo integrity analysis	2–3 weeks
Gut barrier integrity assay panel	3–4 weeks
Immunomodulation profiling panel	3–4 weeks
Comparative strain screen (up to 5 strains, 3 endpoints)	5–6 weeks
Batch consistency evaluation (3 batches, full panel)	6–8 weeks
Integrated functional evaluation package (GI stability + cargo integrity + barrier + immunomodulation)	8–10 weeks
Expedited timeline	Available upon request

Timeline may vary based on strain number, assay complexity, and replicate requirements.

Deliverables

GI stability report: Phase-specific particle retention data, size stability metrics, surface charge trends, digestion vulnerability profile, formulation recommendations.
Cargo integrity report: Quantitative retention data for targeted RNA, protein, and metabolite cargo molecules with analytical methodology documentation.
Barrier function report: TEER time-course data, tight junction protein expression and localization, dose-response curves, positive control benchmarking.
Immunomodulation report: Multi-cytokine dose-response profiles, immune polarization assessment, NF-κB pathway activity data, potency metrics.
Comparative benchmarking report: Strain or batch potency rankings, statistical comparisons, batch consistency analysis, lead candidate identification.
Integrated functional dossier: Combined evaluation package with executive summary, all raw and analyzed data, methodology documentation, and regulatory submission-ready figures.

Quality Control

Pre-digestion baseline characterization: NTA, DLS, and zeta potential on every sample before digestion.
Digestion model validation: pH verification, enzyme activity confirmation, and temperature monitoring for every run.
Assay controls: Positive controls (established barrier repair agents, immunomodulators), negative controls (digestion buffer blank, untreated cells), and vehicle controls on every assay plate.
Intra-assay CV: ≤15% for all quantitative endpoints.
Inter-assay CV: ≤20% for functional assays across independent runs.
Cell line authentication: STR profiling and mycoplasma testing performed quarterly on all continuous cell lines.
Data integrity: Raw data archiving, analysis script versioning, and independent data review for all client reports.

Sample Requirements

Required Information	Optional Information	Not Accepted
mEV sample origin (production strain, fermentation conditions) Sample concentration and total volume provided Buffer composition and storage history Target functional endpoints of interest Intended food product matrix and formulation (if applicable) Prior characterization data (NTA, TEM, protein content)	Strain genome sequence or strain background information Known bioactive cargo molecules of interest Reference comparator samples (competitor product, different formulation) Desired statistical power and replicate number Regulatory framework for data use (GRAS, novel food, health claim) Dose range of interest for functional assays	Samples with visible microbial contamination or turbidity indicative of bacterial growth Samples shipped at ambient temperature without cold-chain preservation mEV preparations in incompatible buffers (detergents, denaturants, organic solvents) Samples without any prior characterization data (concentration unknown) Insufficient volume for the requested assay panel Samples from non-food-grade or pathogenic strains without biosafety documentation

Recommended Sample Volume by Service:

Service Module	Minimum Volume	Recommended Volume
GI stability assessment (single condition)	200 μL at ≥1 × 10¹¹ particles/mL	500 μL at ≥1 × 10¹¹ particles/mL
Post-digestion cargo integrity	300 μL at ≥1 × 10¹¹ particles/mL	500 μL at ≥1 × 10¹¹ particles/mL
Gut barrier integrity assay panel	200 μL at ≥1 × 10¹¹ particles/mL	400 μL at ≥1 × 10¹¹ particles/mL
Immunomodulation profiling panel	200 μL at ≥1 × 10¹¹ particles/mL	400 μL at ≥1 × 10¹¹ particles/mL
Comparative strain screen (per strain)	100 μL at ≥1 × 10¹¹ particles/mL	200 μL at ≥1 × 10¹¹ particles/mL
Integrated evaluation package	1 mL at ≥1 × 10¹¹ particles/mL	2 mL at ≥1 × 10¹¹ particles/mL

Storage & Shipping: Ship purified mEV suspensions in sterile PBS on dry ice with cold-chain documentation. Include a completed sample information sheet with strain origin, production conditions, particle concentration (NTA or DLS), and prior characterization data. For formulation-embedded mEVs, provide the formulation matrix composition and processing history. Samples that have undergone freeze-thaw cycles should note the number of cycles. All samples must be shipped with temperature loggers to verify cold-chain integrity upon receipt.

Inquiry

Our Advantages

Physiologically Relevant Digestion Models — INFOGEST-aligned models replicate human GI pH, enzymes, and bile salts, generating physiologically relevant stability data beyond simplified tests.
Beyond Particle Counting: Cargo-Level Integrity — We quantify sRNA, protein, and metabolite cargo integrity after digestion, proving the functional payload survives GI transit—not just the vesicle shell.
Multi-Endpoint Bioactivity Profiling — Integrated profiling covers gut barrier, immunomodulation, and anti-inflammatory readouts in one study, capturing synergistic probiotic mechanisms.
Comparative Benchmarking Built In — Core strain screening and batch consistency assessment deliver potency rankings, statistical comparisons, and CV analysis for strain selection and product claims.
Regulatory-Grade Data Packages — All data packages include full methodology, raw archiving, and statistical analysis ready for GRAS, novel food, and product registration submissions.
Integrated Production-to-Evaluation Pathway — Functional data feeds directly into production optimization, creating a closed-loop quality-by-design system that informs manufacturing decisions.

Applications

3D scene showing a regulatory document with data charts and health claim text, supported by GI stability curves, barrier repair data, and immunomodulation dose-response plots.

Functional Food Health Claim Substantiation

GI stability and bioactivity data packages supporting structure-function claims, health claims, and product differentiation for functional food and nutraceutical marketing.

3D scene showing a competitive landscape comparison with potency rankings, a radar chart of multi-endpoint bioactivity, and a product label with a differentiation badge.

Probiotic Product Differentiation

Head-to-head functional benchmarking against competitor EV preparations or conventional probiotics, generating evidence for superior efficacy positioning.

3D scene showing a medical food product with gut barrier repair data, anti-inflammatory cytokine profiles, and a clinical study protocol document.

Medical Food Clinical Support

Mechanistic efficacy data supporting the rationale for medical food and FSMP product development targeting gut barrier dysfunction and intestinal inflammation.

3D scene showing a regulatory dossier with scientific evidence tabs, including GI stability data, functional assay results, and batch consistency analysis.

GRAS & Novel Food Dossier Evidence

Quantitative stability and bioactivity data formatted for inclusion in GRAS self-affirmation packages, EFSA novel food applications, and international regulatory submissions.

Case Study

Case Study: Comparative Functional Profiling Reveals Strain-Specific Bioactivity of Probiotic EVs

The researchers compared bEVs from eight Lactobacillales strains, characterizing particle properties, uptake, transcriptomics, and bioactivity. Lactococcus lactis yielded the highest vesicle output (3.2 × 10⁹ particles/mL), L. plantarum carried the highest protein content (0.124 pg/particle), and L. plantarum and L. salivarius both exhibited the highest lipid content (16.3 pg/particle each). Connectivity Map analysis predicted skin health applications for L. fermentum (connectivity score 99.92 with hydrocortisone), L. rhamnosus (96.15 with acitretin), and L. acidophilus (95.10 with retinol). NIH3T3 fibroblast validation confirmed collagen synthesis enhancement up to 1.25-fold via pSMAD3/HSP47 upregulation and MMP1 downregulation, mapping to JAK-STAT, PI3K-AKT, and focal adhesion pathways.

Panel of bar charts and dose-response curves showing collagen synthesis enhancement by bacterial extracellular vesicles from eight Lactobacillales strains in NIH3T3 fibroblasts, with Sirius Red staining quantification and ELISA confirmation.
Figure 2. Collagen synthesis enhancement by bacterial extracellular vesicles from eight Lactobacillales strains in NIH3T3 fibroblasts, showing dose-dependent collagen production measured by Sirius Red staining and ELISA, with Western blot analysis of pSMAD3, HSP47, and MMP1 regulatory proteins. (Park, et al. 2025)

FAQs

Q: How do simulated GI digestion conditions compare to actual human digestion?

A: Our INFOGEST-aligned static digestion model replicates the key biochemical parameters of human GI transit: gastric phase at pH 2.0 with physiologically relevant pepsin activity, followed by intestinal phase at pH 6.8 with pancreatin and bile salts at concentrations matching fasted-state human intestinal fluid. While static models do not capture the dynamic emptying and peristaltic mixing of in vivo digestion, they provide standardized, reproducible conditions that are the international consensus method for food digestion research and are accepted by regulatory bodies for stability evidence in GRAS and novel food dossiers.

Q: What is the difference between particle retention and cargo integrity?

A: Particle retention measures whether the vesicle structure remains intact after digestion—it answers “did the particle survive?” Cargo integrity measures whether the bioactive molecules inside the vesicle—sRNAs, proteins, metabolites—remain structurally intact and functionally competent. A vesicle can retain its particle structure while its internal cargo degrades. Our service quantifies both, providing a complete picture of functional survival through GI transit.

Q: Can you test mEVs already formulated into a food matrix?

A: Yes. We can evaluate mEVs embedded in food matrices including liquid beverages, semi-solid gels, dry powders, and encapsulated formulations. The digestion protocol is adjusted to reflect the matrix composition—for example, incorporating a simulated oral phase with amylase for starch-containing products, or a gastric phase with adjusted pH and pepsin levels for protein-rich matrices. This provides formulation-specific stability data rather than generic buffer-only results.

Q: How many replicates are needed for statistically meaningful functional data?

A: Our standard evaluation runs n = 3 biological replicates per condition for GI stability and cargo integrity assays, and n = 3–4 replicates for cell-based functional assays, which provides sufficient statistical power to detect ≥30% effect sizes with 80% power at α = 0.05. For regulatory submissions requiring higher statistical rigor, we can increase replicate numbers and include pre-specified statistical analysis plans. Comparative strain screens with 5+ strains typically use n = 3 replicates with ANOVA and post-hoc correction for multiple comparisons.

Q: Do you offer in vivo evaluation of food-grade mEV function?

A: Our core evaluation platform focuses on in vitro and ex vivo models, which provide the standardized, reproducible data most commonly required for GRAS and novel food dossiers. For clients requiring in vivo confirmation, we offer tiered pathways into pharmacokinetic biodistribution studies, acute and subchronic oral toxicity assessment, and disease-model efficacy testing in rodent models. These services are scoped and quoted on a project-specific basis and can integrate with our Exosome Functional Validation & Mechanism of Action Studies platform.

Q: How do you ensure that functional assay results are not driven by non-EV components?

A: We include rigorous controls to attribute bioactivity specifically to mEVs: vesicle-depleted supernatant controls confirm that activity is particle-associated; digestion buffer blanks rule out assay interference from digestion reagents; and protein-normalized dosing ensures that comparisons between strains or batches reflect genuine potency differences rather than concentration artifacts. For immunomodulation assays, polymyxin B controls are included to rule out endotoxin-driven effects when working with Gram-negative mEV preparations.

Q: Can functional evaluation data support a health claim submission?

A: Yes. Our functional evaluation reports are structured with full analytical methodology documentation, raw data archiving, statistical analysis, and regulatory-ready figures suitable for inclusion in: FDA structure-function claim notifications, EFSA health claim applications under Regulation (EC) 1924/2006, GRAS self-affirmation safety and efficacy sections, and novel food authorization dossiers. We do not submit claims on your behalf, but we provide the technical evidence package that your regulatory affairs team needs to prepare submissions.

References:

Park, S., et al. (2025). Comparative and pharmacological investigation of bEVs from eight Lactobacillales strains. Scientific Reports, 15, 12873.

Services

Inquiry